Eisai Draws U.S. FDA Warning Letter For Misleading Efficacy and Safety Claims
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - U.S. FDA issued a warning letter to Eisai for "serious" violations regarding a Dacogen (decitabine) marketing document that minimize risk and "greatly overstates the efficacy of Dacogen.
You may also be interested in...
Eisai Eyes New Product Launches, Strong Growth In Asia To Offset Aricept Patent Loss
Preparing for patent expiry for blockbuster Alzheimer's disease drug Aricept (donepezil) in November, Eisai will step up efforts to launch new products in the fiscal year, company President Haruo Naito said during the company's Feb. 2 earnings conference call
Eisai Eyes New Product Launches, Strong Growth In Asia To Offset Aricept Patent Loss
Preparing for patent expiry for blockbuster Alzheimer's disease drug Aricept (donepezil) in November, Eisai will step up efforts to launch new products in the fiscal year, company President Haruo Naito said during the company's Feb. 2 earnings conference call
DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks
Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.